Dual-Site Transcranial Magnetic Stimulation of the Supplementary Motor Area and Cerebellum for the Treatment of Essential Tremor.

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Essential Tremor

In brief

Essential tremor is a common movement disorder that causes involuntary shaking, mainly during voluntary actions such as writing or holding objects. Recent research suggests that essential tremor is not caused by a single brain area, but by abnormal activity within a network that includes the cerebellum and motor areas of the brain. However, most non-invasive brain stimulation studies to date have targeted only one brain region and have shown inconsistent clinical benefits. This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of a dual-site transcranial magnetic stimulation (rTMS) protocol targeting the supplementary motor area (SMA) and the cerebellum in patients with essential tremor that does not respond adequately to standard medications. The study is based on previous pilot data showing meaningful tremor reduction using combined stimulation of these two brain regions. Participants will receive five sessions of rTMS, consisting of low-frequency stimulation over the SMA followed by high-frequency stimulation over the cerebellum. The main hypothesis is that this combined approach will lead to an immediate and sustained improvement in action tremor of the dominant upper limb, measured up to four weeks after treatment. Secondary outcomes include quality of life, safety, side effects, and changes in brain excitability associated with tremor improvement.

Key facts

Study ID

NCT07344194

Run by

São Paulo State University

People needed

36

Starts

2026-01-15

Expected to finish

2027-01-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female participants, aged 18 to 80 years; women of childbearing potential must not be pregnant.
• Diagnosis of Essential Tremor with a score greater than 2 on items 5 or 6 of the Fahn-Tolosa-Marin Tremor Rating Scale despite optimized medical therapy.
• Medication-refractory tremor, defined as prior use of both first-line medications (propranolol and primidone) at maximally tolerated doses without adequate tremor control.
• Ability to provide written informed consent in accordance with institutional policies.
• Ability to comply with all study procedures and follow-up assessments as defined by the study protocol.

You may not qualify if…

• Unstable or untreated psychiatric disorders.
• Inability to provide informed consent.
• Uncontrolled medical conditions, including but not limited to uncontrolled diabetes mellitus, hypertension, symptomatic pulmonary disease, or symptomatic cardiac disease.
• Concomitant participation in another investigational drug or device study.
• Pregnancy or breastfeeding.
• Presence of an implanted deep brain stimulation (DBS) system.
• History of epilepsy not adequately controlled, defined as seizure-free for less than 5 years.
• Presence of a cardiac pacemaker.
• Presence of metallic implants in any part of the body that are contraindicated for rTMS.

Where it is running

• Sao Paulo University — São Paulo, São Paulo, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.